

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: 131MIBG to Treat Malignant Pheochromocytoma

OBJECTIVE OF STUDY: To determine the effectiveness of 131MIBG in treating malignant pheochromocytoma and whether sensitization medications improve the response to treatment

MINIMUM ELIGIBILITY REQUIREMENTS: Patients 18 years of age and older (up to age 70)

PARTICIPANT ACTIVITIES (*office visits, tests, take medications, etc*): Participants will be hospitalized for 3-5 days for each 131MIBG treatment, there will be up to 3 treatments over a 3-month period, patients will be required to take potassium (2x a day for 30 days) to protect the thyroid gland, after each treatment, patients will have a clinical evaluation and periodic blood tests to test for side effects, follow-up visits will be scheduled at NIH at 12 and 18 months after first treatment, patients with lung tumors will have lung function tests 1, 3, and 6 months after each treatment

CONTACT INFORMATION: **COORDINATOR / CHAIR** (*please circle one*)

NAME/TITLE: National Institute of Child Health and Human Development (NICHD)

AFFILIATION: Patient Recruitment and Public Liaison Office

MAILING ADDRESS: Durham, NC USA

PHONE: 800.411.1222

Email ADDRESS: prpl@mail.cc.nih.gov

WEBSITE (*for complete info*): <http://clinicaltrials.gov/ct/show/NCT00028106?order=2>